Bayer announced that the Chinese National Medical Products Administration (NMPA) has granted marketing authorization for finerenone under the brand name Kerendia. Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is indicated for the treatment of chronic kidney disease (CKD) (eGFR of = 25 to 75 mL/min/1.73 m2 with albuminuria) associated with type 2 diabetes (T2D) in adults, to reduce the risk of sustained eGFR decline and end-stage kidney disease. The approval of Kerendia in China is based on the results of the pivotal phase III study FIDELIO-DKD, presented at the American Society of Nephrology
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!